再次：PD-L1阳性作为尿路上皮癌免疫检查点阻断的生物标志物。

IF 8.1 1区医学 Q1 IMMUNOLOGY

Cancer immunology research Pub Date : 2025-04-02 DOI:10.1158/2326-6066.CIR-25-0202

Arivarasan Karunamurthy, Diwakar Davar

{"title":"再次：PD-L1阳性作为尿路上皮癌免疫检查点阻断的生物标志物。","authors":"Arivarasan Karunamurthy, Diwakar Davar","doi":"10.1158/2326-6066.CIR-25-0202","DOIUrl":null,"url":null,"abstract":"Biomarkers of responsiveness to immune checkpoint blockade (ICB) are heavily sought given the breadth and depth of the use of ICB in cancer. PD-L1 expression was among the first biomarkers identified, but multiple factors have precluded more widespread use. In this issue, Galsky and colleagues utilize two separate PD-L1 assays to study urothelial carcinoma specimens and observe that SP142 (relative to 22C3) preferentially stains dendritic cells. These observations may help reconcile the discordant performance of the two PD-L1 assays in ICB-treated urothelial carcinoma while underscoring the role of dendritic cells in orchestrating ICB response. See related article by Galsky et al., p. 476 .","PeriodicalId":9474,"journal":{"name":"Cancer immunology research","volume":" ","pages":"454-455"},"PeriodicalIF":8.1000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial Carcinoma.\",\"authors\":\"Arivarasan Karunamurthy, Diwakar Davar\",\"doi\":\"10.1158/2326-6066.CIR-25-0202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biomarkers of responsiveness to immune checkpoint blockade (ICB) are heavily sought given the breadth and depth of the use of ICB in cancer. PD-L1 expression was among the first biomarkers identified, but multiple factors have precluded more widespread use. In this issue, Galsky and colleagues utilize two separate PD-L1 assays to study urothelial carcinoma specimens and observe that SP142 (relative to 22C3) preferentially stains dendritic cells. These observations may help reconcile the discordant performance of the two PD-L1 assays in ICB-treated urothelial carcinoma while underscoring the role of dendritic cells in orchestrating ICB response. See related article by Galsky et al., p. 476 .\",\"PeriodicalId\":9474,\"journal\":{\"name\":\"Cancer immunology research\",\"volume\":\" \",\"pages\":\"454-455\"},\"PeriodicalIF\":8.1000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer immunology research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2326-6066.CIR-25-0202\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer immunology research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2326-6066.CIR-25-0202","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

考虑到免疫检查点阻断（ICB）在癌症中的广泛和深入应用，对ICB反应性的生物标志物被大量寻找。PD-L1表达是最早确定的生物标志物之一，但多种因素阻碍了更广泛的应用。在这一期中，Galsky及其同事利用两种单独的PD-L1检测来研究尿路上皮癌标本，并观察到SP142（相对于22C3）优先染色树突状细胞。这些观察结果可能有助于调和两种PD-L1测定在ICB治疗的尿路上皮癌中的不一致表现，同时强调树突状细胞在协调ICB反应中的作用。参见Galsky等人的相关文章，第XX页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial Carcinoma.

Biomarkers of responsiveness to immune checkpoint blockade (ICB) are heavily sought given the breadth and depth of the use of ICB in cancer. PD-L1 expression was among the first biomarkers identified, but multiple factors have precluded more widespread use. In this issue, Galsky and colleagues utilize two separate PD-L1 assays to study urothelial carcinoma specimens and observe that SP142 (relative to 22C3) preferentially stains dendritic cells. These observations may help reconcile the discordant performance of the two PD-L1 assays in ICB-treated urothelial carcinoma while underscoring the role of dendritic cells in orchestrating ICB response. See related article by Galsky et al., p. 476 .

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer immunology research ONCOLOGY-IMMUNOLOGY

CiteScore

15.60

自引率

1.00%

发文量

260

期刊介绍： Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes. Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.